JP2012228272A5 - - Google Patents

Download PDF

Info

Publication number
JP2012228272A5
JP2012228272A5 JP2012187518A JP2012187518A JP2012228272A5 JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5 JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5
Authority
JP
Japan
Prior art keywords
framework
single chain
chain framework
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012187518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012228272A (ja
JP6075836B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012228272A publication Critical patent/JP2012228272A/ja
Publication of JP2012228272A5 publication Critical patent/JP2012228272A5/ja
Application granted granted Critical
Publication of JP6075836B2 publication Critical patent/JP6075836B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012187518A 2002-05-22 2012-08-28 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 Expired - Lifetime JP6075836B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US60/382,649 2002-05-22
US43825603P 2003-01-03 2003-01-03
US60/438,256 2003-01-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010060713A Division JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013019425A Division JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Publications (3)

Publication Number Publication Date
JP2012228272A JP2012228272A (ja) 2012-11-22
JP2012228272A5 true JP2012228272A5 (enExample) 2013-03-21
JP6075836B2 JP6075836B2 (ja) 2017-02-08

Family

ID=29553590

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2004506369A Withdrawn JP2006508638A (ja) 2002-05-22 2003-05-21 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2010060713A Withdrawn JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2012187518A Expired - Lifetime JP6075836B2 (ja) 2002-05-22 2012-08-28 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013019425A Expired - Lifetime JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013193935A Pending JP2013256533A (ja) 2002-05-22 2013-09-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161601A Pending JP2015214583A (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161600A Expired - Lifetime JP6261136B2 (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2017161036A Pending JP2017201990A (ja) 2002-05-22 2017-08-24 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2019009288A Expired - Lifetime JP6918033B2 (ja) 2002-05-22 2019-01-23 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2020085288A Pending JP2020171286A (ja) 2002-05-22 2020-05-14 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004506369A Withdrawn JP2006508638A (ja) 2002-05-22 2003-05-21 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2010060713A Withdrawn JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2013019425A Expired - Lifetime JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013193935A Pending JP2013256533A (ja) 2002-05-22 2013-09-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161601A Pending JP2015214583A (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161600A Expired - Lifetime JP6261136B2 (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2017161036A Pending JP2017201990A (ja) 2002-05-22 2017-08-24 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2019009288A Expired - Lifetime JP6918033B2 (ja) 2002-05-22 2019-01-23 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2020085288A Pending JP2020171286A (ja) 2002-05-22 2020-05-14 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Country Status (14)

Country Link
US (5) US8853362B2 (enExample)
EP (5) EP3656787A1 (enExample)
JP (10) JP2006508638A (enExample)
CN (4) CN105175535A (enExample)
AU (2) AU2003238370B2 (enExample)
CA (2) CA2867542C (enExample)
CY (1) CY1114225T1 (enExample)
DK (2) DK2332989T3 (enExample)
ES (3) ES2656427T3 (enExample)
HU (1) HUE048922T2 (enExample)
NZ (1) NZ536412A (enExample)
PT (2) PT2332989E (enExample)
SI (2) SI2332989T1 (enExample)
WO (1) WO2003097697A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
WO2006099747A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
EP2013236B1 (en) * 2006-04-28 2015-06-17 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
AU2007272224B2 (en) 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
CN103275216B (zh) * 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
CN101842388B (zh) 2007-09-13 2013-09-04 德勒尼克斯治疗股份公司 针对β淀粉样肽的人源化抗体
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
ES2771150T3 (es) * 2008-06-25 2020-07-06 Novartis Ag Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
ES2890405T3 (es) 2008-06-25 2022-01-19 Novartis Ag Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
ES2687259T5 (es) * 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
US9556265B2 (en) 2008-06-25 2017-01-31 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
CA2729185A1 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for modifying immunobinders
EP2303230A2 (en) 2008-07-10 2011-04-06 ESBATech, an Alcon Biomedical Research Unit LLC Methods and compositions for enhanced delivery of macromolecules
RU2577965C2 (ru) * 2009-02-24 2016-03-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Способ идентификации иммунных связывающих веществ поверхностных антигенов клетки
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
DK2744931T3 (en) 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
AR088403A1 (es) 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc Anticuerpo de union a multiples antigenos estable
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
US9404930B2 (en) 2012-11-05 2016-08-02 Delenex Therapeutics Ag Antibody to human IL-1 beta
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
JP2016506974A (ja) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
HK1219485A1 (zh) 2013-02-20 2017-04-07 Esbatech - A Novartis Company Llc 用於cdr移植的受体框架
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2018004515A (es) * 2015-10-13 2019-04-15 Eureka Therapeutics Inc Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CN116059316A (zh) 2015-10-23 2023-05-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
AU2017331256B2 (en) 2016-09-21 2024-11-07 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
CN112218621A (zh) * 2018-04-10 2021-01-12 西北大学 包含基于靶向亲和域的膜蛋白的胞外囊泡
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US11524998B2 (en) 2020-07-16 2022-12-13 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3172265A1 (en) 2021-03-10 2022-09-15 Dimitri BIELI Antibodies against tdp-43 and methods of using the same
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
ATE273323T1 (de) 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Similar Documents

Publication Publication Date Title
JP2014515602A5 (enExample)
FI3936521T3 (fi) Heterodimeerisiä proteiineja
López-Marqués et al. Structure and mechanism of ATP-dependent phospholipid transporters
JP2018531624A5 (enExample)
BRPI0813898A2 (pt) métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira.
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
IL258102A (en) Immunomodulatory transmembrane proteins containing domain variants of the immunoglobulin superfamily, nucleic acids encoding them, vectors and cells expressing them and uses thereof
Zhou et al. Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses
JP2010227108A5 (enExample)
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2016502843A5 (enExample)
JP2016185981A5 (enExample)
JP2017048194A5 (enExample)
JP2020501532A5 (enExample)
JP2013172734A5 (enExample)
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
WO2015089486A3 (en) Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
WO2016168755A8 (en) Method for mass humanization of non-human antibodies
JP2013539454A5 (enExample)
WO2012142434A8 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
JP2017514522A5 (enExample)
JP2014511682A5 (enExample)
JP2012505657A5 (enExample)
WO2016130628A8 (en) Griffithsin mutants